Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD:: a discrimination from Alzheimer's disease?

被引：114

作者：

Kapaki, E ^{[1
]}

Kilidireas, K ^{[1
]}

Paraskevas, GP ^{[1
]}

Michalopoulou, M ^{[1
]}

Patsouris, E ^{[1
]}

机构：

[1] Athens Natl Univ, Aeginit Hosp, Sch Med, Dept Neurol, Athens 11528, Greece

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2001年 / 71卷 / 03期

关键词：

Creutzfeldt-Jakob disease; Alzheimer's disease; tau protein; beta-amyloid; 1-42;

D O I：

10.1136/jnnp.71.3.401

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The aim was to quantify tau protein and beta -amyloid (A beta 42) in the CSF of patients with sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), and controls. Double sandwich enzyme linked immunosorbent assays (ELISAs) were used for measurments. Tau was increased 58-fold in CJD and 3.5-fold in AD compared with controls, whereas A beta 42 was decreased 0.5-fold in both CJD and AD. A cut off level for tau protein at 2131 pg/ml successfully discriminated CJD from AD (100% specificity and 93% sensitivity). Tau protein concentration in CSF is probably an additional useful marker in differentiating CJD from AD.

引用

页码：401 / 403

页数：3

共 14 条

[1]

BARCIKOWSKA M, 1995, HISTOPATHOLOGY, V26, P445

[2] Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease [J].

Hainfellner, JA ;

Wanschitz, J ;

Jellinger, K ;

Liberski, PP ;

Gullotta, F ;

Budka, H .

ACTA NEUROPATHOLOGICA, 1998, 96 (02) :116-122

[3] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].

Hulstaert, F ;

Blennow, K ;

Ivanoiu, A ;

Schoonderwaldt, HC ;

Riemenschneider, M ;

De Deyn, PP ;

Bancher, C ;

Cras, P ;

Wiltfang, J ;

Mehta, PD ;

Iqbal, K ;

Pottel, H ;

Vanmechelen, E ;

Vanderstichele, H .

NEUROLOGY, 1999, 52 (08) :1555-1562

[4] Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies [J].

Kanemaru, K ;

Kameda, N ;

Yamanouchi, H .

NEUROLOGY, 2000, 54 (09) :1875-1876

[5] Increased cerebrospinal fluid tau protein in multiple sclerosis [J].

Kapaki, E ;

Paraskevas, GP ;

Michalopoulou, M ;

Kilidireas, K .

EUROPEAN NEUROLOGY, 2000, 43 (04) :228-232

[6]

MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939

[7] REDUCTION OF BETA-AMYLOID PEPTIDE(42), IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH ALZHEIMERS-DISEASE [J].

MOTTER, R ;

VIGOPELFREY, C ;

KHOLODENKO, D ;

BARBOUR, R ;

JOHNSONWOOD, K ;

GALASKO, D ;

CHANG, L ;

MILLER, B ;

CLARK, C ;

GREEN, R ;

OLSON, D ;

SOUTHWICK, P ;

WOLFERT, R ;

MUNROE, B ;

LIEBERBURG, I ;

SEUBERT, P ;

SCHENK, D .

ANNALS OF NEUROLOGY, 1995, 38 (04) :643-648

[8] Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease [J].

Otto, M ;

Esselmann, H ;

Schulz-Schaeffer, W ;

Neumann, M ;

Schröter, A ;

Ratzka, P ;

Cepek, L ;

Zerr, I ;

Steinacker, P ;

Windl, O ;

Kornhuber, J ;

Kretzschmar, HA ;

Poser, S ;

Wiltfang, J .

NEUROLOGY, 2000, 54 (05) :1099-1102

[9] Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease [J].

Otto, M ;

Wiltfang, J ;

Tumani, H ;

Zerr, I ;

Lantsch, M ;

Kornhuber, J ;

Weber, T ;

Kretzschmar, HA ;

Poser, S .

NEUROSCIENCE LETTERS, 1997, 225 (03) :210-212

[10] Alzheimer's disease and the amyloid β protein:: What is the role of amyloid? [J].

Small, DH ;

McLean, CA .

JOURNAL OF NEUROCHEMISTRY, 1999, 73 (02) :443-449

← 1 2 →